Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Satellos Bioscience Inc.

< Previous 1 2 Next >
News headline image
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Appoints Stephanie Brown to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Reports Q3 2024 Financial Results and Provides Clinical Update
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in November 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Participation in September 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Present at Upcoming Virtual Investor Conferences in March and April
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Recognized as a Top 50 TSX Venture Exchange Company
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX:MSCL
News headline image
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos to Commence Trading on the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
News headline image
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.